Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program

GBI Research, April 2012, Pages: 53

GBI Research, the leading business intelligence provider, has released its latest research “Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program”. It provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in Russia, with key data, information and analysis of the steps of the pricing and reimbursement process.

The report closely scrutinizes major changes in the pharmaceuticals-related pricing and reimbursement in Russia due to the implementation of a new law “On Circulation of Drugs”.

The scenario of pricing and reimbursement of drugs in Russia is in a dynamic phase. The government of Russia increased the funding of National Healthcare Project to improve the primary healthcare provided to Russians. Under the National Healthcare Project, improvement in primary healthcare, out-patient clinics and technology centers was done.

The launch of the DLO (the acronym for Additional Medicines Supply Program) program was done for disabled persons, pensioners and patients in need of specialized medicines. It was estimated by the Ministry of Health and Social Development that 15 million people will be covered under this program. Since the option of opting for money instead of medicine was provided under the program, a greater number of patients opted for the money. Those patients who opted for medicines got a chance to be treated by some of the best medicines available for their respective therapy areas.

The VZN program (acronym for Seven Nosologies Program) was segmented from the DLO. This was because there is a set of people who need specialized medicines which are particularly expensive. The other segment of the DLO program is called the Essential Drug Program (ONLS). Compulsory medical insurance for all Russians was introduced in 1995. Under the medical insurance plan Russians recieve treatment, hospitalization, surgical operation, dental care and other facilities free of charge.

However, state medical insurance does not seem to be sufficient for all Russians, so private insurance (voluntary medical insurance) players are also active in the field. The implementation of the new law “on circulation of drugs” resulted in the mandatory registration of prices of drugs listed in the Essential Drug List (EDL) in Russia.

This means that the Russian government will now regulate the prices of drugs more uniformly. The decision of the Russian government to boost the domestic pharmaceutical market will lead to the launch of more innovative drugs by domestic pharmaceutical companies. Many major global pharmaceutical companies are initiating and expanding their production capacities in Russia to penetrate further into this market.

Scope

- Detailed study of the healthcare scenario in the Russia.

- Analysis of the pricing and reimbursement mechanisms in Russia.

- Key changes that follow from the implementation of new law “on circulation of drugs” in the pricing and reimbursement system.

- Details about government bodies which regulate different processes of pricing and reimbursement in Russia.

- Details about share of major companies in reimbursement program of Russia.

- Insight into various reimbursement programs in Russia.

Reasons to buy

- Build an understanding of the pharmaceuticals-related key pricing and reimbursement mechanisms in Russia.

- Optimize your investment through identification and understanding of the changes in the pharmaceutical regulatory mechanism in Russia.

- Knowledge about the regulatory bodies who undertake different processes of price registration.

- Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in pricing and reimbursement scene in Russia.

- Negotiate better with the government agencies to maximize reimbursement on the drugs by understanding the mechanism.

1.1 List of Tables
1.2 List of Figures

2 Pricing and Reimbursement in Russia - Introduction
2.1 GBI Research Report Guidance

3 Pricing and Reimbursement in Russia - Overview
3.1 Introduction to Healthcare System in Russia
3.1.1 Comparative Analysis

4 Pricing and Reimbursement in Russia - Overview of Pharmaceutical Market in Russia
4.1 Healthcare System in Russia
4.1.1 Health Indicators in Russia
4.1.2 Private Expenditure on Health
4.1.3 Segmentation of Russian Pharmaceutical Market
4.2 PEST Analysis of Russian Pharmaceutical Market
4.2.1 Political
4.2.2 Economical
4.2.3 Social
4.2.4 Technological
4.3 Drug Expenditure
4.3.1 Drug Expenditure as Percentage of Healthcare Expenditure
4.4 Russian Pharmaceutical Market Segmented by Therapeutic Area

5 Pricing and Reimbursement in Russia - Drug Pricing in Russia
5.1 Introduction
5.1.1 Drug Price Authorities in Russia
5.1.2 Price Registration in Russia
5.2 Price Setting Procedures
5.2.1 Essential Drugs List (EDL) Pricing
5.2.2 Historical Pricing Procedures
5.2.3 Current Pricing Procedures
5.2.4 Reasons to Change Prevailing Pricing Procedures
5.3 Type of Compensation for EDL Drugs
5.4 Share of Domestic Drugs in EDL
5.4.1 Share of Domestic Drugs in EDL by Sales Value
5.4.2 Share of Domestic Drugs in EDL by Sales Volume
5.5 Share of EDL in Russian Pharmaceutical Market
5.5.1 Share of EDL in Russian Pharmaceutical Market by Sales Value
5.5.2 Share of EDL Drugs in Russian Pharmaceutical Market by Sales Volume

6 Pricing and Reimbursement in Russia - Reimbursement Programs in Russia
6.1 Introduction
6.1.1 DLO - Reimbursement Program of Russia
6.1.2 The Seven Nosologies Program (VZN)
6.1.3 ONLS Program
6.2 Insurance System

7 Pricing and Reimbursement in Russia - Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Research Methodology
7.3.1 Healthcare System
7.3.2 Pharmaceutical Regulations
7.3.3 Pricing of Pharmaceutical Drugs
7.3.4 Reimbursement of Pharmaceutical Drugs
7.3.5 Pricing and Reimbursement in Major Therapy Areas
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

1.1 List of Tables
Table 1: Pricing and Reimbursement in Russia, Health Expenditure as a Percentage of GDP ($), %, BRIC and The US, 2006-2009
Table 2: Pricing and Reimbursement in Russia, Estimated Public Health Spending as a percentage of GDP, BRIC vs The US, 2010-2050
Table 3: Pricing and Reimbursement in Russia, Public Health Expenditure as a Percentage of Total Health Expenditure ($), BRIC and the US, 2006-2009
Table 4: Pricing and Reimbursement in Russia, Health Expenditure per Capita ($), BRIC Countries, 2006-2009
Table 5: Pricing and Reimbursement in Russia, Out of Pocket Health Expenditure as a Percentage of Private Expenditure on Health, BRIC, The US, 2006-2009
Table 6: Pricing and Reimbursement in Russia, Health Indicators, Russia, 2009
Table 7: Pricing and Reimbursement in Russia, Share of Domestic and Imported Drugs, Sales Value, %, Russia, 2009 and 2010
Table 8: Pricing and Reimbursement in Russia, Share of Domestic and Imported Drugs, Sales Volume, %, Russia, 2009 and 2010
Table 9: Pricing and Reimbursement in Russia, Share of Prescription and OTC Drugs, Sales Value, %, Russia, 2009 and 2010
Table 10: Pricing and Reimbursement in Russia, Share of Prescription and OTC Drugs, Sales Volume, %, Russia, 2009 and 2010
Table 11: Pricing and Reimbursement in Russia, Private Expenditure on Health as a Percentage of Total Healthcare Expenditure, Russia, 2000-2009
Table 12: Pricing and Reimbursement in Russia, Total Expenditure on Health per Capita at Exchange Rate, ($), Russia, 2000-2009
Table 13: Pricing and Reimbursement in Russia, Pharmaceutical Market Segmentation, Sales Value, %, Russia, 2009-2010
Table 14: Pricing and Reimbursement in Russia, Segmentation of Out of Pocket Drug Market by Price of Drugs, %, Russia, 2009-2010
Table 15: Pricing and Reimbursement in Russia, Russian Pharmaceutical Market, Therapy Area, Sales Value, %, 2009-2010
Table 16: Pricing and Reimbursement in Russia, Russian Pharmaceutical Market, Therapy Area, Sales Volume, %, 2009-2010
Table 17: Pricing and Reimbursement in Russia, Share of Domestic Drugs in EDL, Sales Value, %, Russia, 2009-2010
Table 18: Pricing and Reimbursement in Russia, Share of Domestic Drugs in EDL, Sales Volume, %, Russia, 2009-2010
Table 19: Pricing and Reimbursement in Russia, Share of EDL in Total Russian Pharmaceutical Market, Sales Value, %, Russia, 2009-2010
Table 20: Pricing and Reimbursement in Russia, Share of EDL in Total Russian Pharmaceutical Market, Sales Volume, %, Russia, 2009-2010
Table 21: Pricing and Reimbursement in Russia, Number of DLO Beneficiaries, million, Russia, 2005-2010
Table 22: Pricing and Reimbursement in Russia, Total Value of DLO Program, Russia, 2007-2010
Table 23: Pricing and Reimbursement in Russia, Segmentation of DLO Sector Based on Sales Value of Domestic and Imported Drugs, 2009-2010
Table 24: Pricing and Reimbursement in Russia, Segmentation of DLO Sector Based on Sales Volume of Domestic and Imported Drugs, 2008-2009
Table 25: Pricing and Reimbursement in Russia, Top 10 Companies in DLO Sector, Sales Value, %, Russia, 2009-2010
Table 26: Pricing and Reimbursement in Russia, Top 15 Companies in DLO Sector, Sales Value, %, Russia, 2008-2010
Table 27: Pricing and Reimbursement in Russia, Segmentation of Drugs in DLO Program by Price Range, Sales Value, %, 2009-2010
Table 28: Pricing and Reimbursement in Russia, Segmentation of DLO Program, Sales Value. %, Russia, 2009-2010
Table 29: Pricing and Reimbursement in Russia, Share of Nosologies in Seven Nosologies Program, Russia, (%), 2008-2009
Table 30: Pricing and Reimbursement in Russia, Share of Drugs in Seven Nosologies Program, %, 2009-2010
Table 31: Pricing and Reimbursement in Russia, Share of Drugs in Seven Nosologies Program, %, Russia, 2008-2009
Table 32: Pricing and Reimbursement in Russia, Segmentation of Drugs in VZN Program by Price Range, Sales Value, %, 2009-2010
Table 33: Pricing and Reimbursement in Russia, Price Segmentation of Drugs in ONLS Program, Sales Value, %, Russia, 2009-2010
Table 34: Pricing and Reimbursement in Russia, Private Insurance as a Percentage of Private Healthcare Expenditure, 2000-2009

1.2 List of Figures
Figure 1: Pricing and Reimbursement in Russia, Health Expenditure as a Percentage of GDP ($), %, BRIC and The US, 2006–2009
Figure 2: Pricing and Reimbursement in Russia, Estimated Public Health Spending as a Percentage of GDP, BRIC vs The US, 2010–2050
Figure 3: Pricing and Reimbursement in Russia, Public Health Expenditure as a Percentage of Total Health Expenditure ($), BRIC and the US, 2006–2009
Figure 4: Pricing and Reimbursement in Russia, Health Expenditure per Capita ($), BRIC Countries, 2006–2009
Figure 5: Pricing and Reimbursement in Russia, Out of Pocket Health Expenditure as a Percentage of Private Expenditure on Health, BRIC, The US, 2006–2009
Figure 6: Pricing and Reimbursement in Russia, Share of Domestic and Imported Drugs, Sales Value, %, Russia, 2009 and 2010
Figure 7: Pricing and Reimbursement in Russia, Share of Domestic and Imported Drugs, Sales Volume, %, Russia, 2009 and 2010
Figure 8: Pricing and Reimbursement in Russia, Share of Prescription and OTC Drugs, Sales Value, %, Russia, 2009 and 2010
Figure 9: Pricing and Reimbursement in Russia, Share of Prescription and OTC Drugs, Sales Volume, %, Russia, 2009 and 2010
Figure 10: Pricing and Reimbursement in Russia, Private Expenditure on Health as a Percentage of Total Healthcare Expenditure, Russia, 2000–2009
Figure 11: Pricing and Reimbursement in Russia, Total Expenditure on Health per Capita at Exchange Rate, ($), Russia, 2000–2009
Figure 12: Pricing and Reimbursement in Russia, Pharmaceutical Market Segmentation, Sales Value, %, Russia, 2009–2010
Figure 13: Pricing and Reimbursement in Russia, PEST Analysis of Russian Pharmaceutical Market, 2011
Figure 14: Pricing and Reimbursement in Russia, Segmentation of Out of Pocket Drug Market by Price of Drugs, %, Russia, 2009–2010
Figure 15: Pricing and Reimbursement in Russia, Russian Pharmaceutical Market, Therapy Area, Sales Value, %, 2009–2010
Figure 16: Pricing and Reimbursement in Russia, Russian Pharmaceutical Market, Therapy Area, Sales Volume, %, 2009–2010
Figure 17: Pricing and Reimbursement in Russia, Steps for Entering Pricing and Reimbursement, Russia, 2009
Figure 18: Pricing and Reimbursement in Russia, Steps for EDL Formation, Russia, 2009
Figure 19: Pricing and Reimbursement in Russia, Steps for Price Registration, Russia, 2009
Figure 20: Pricing and Reimbursement in Russia, Registration of Maximum Selling Price of Foreign - Manufactured Drugs, Currency of Price Registration, Russia, 2011
Figure 21: Pricing and Reimbursement in Russia, Types of Compensation for EDL Drugs, Russia, 2011
Figure 22: Pricing and Reimbursement in Russia, Share of Domestic Drugs in EDL, Sales Value, %, Russia, 2009–2010
Figure 23: Pricing and Reimbursement in Russia, Share of Domestic Drugs in EDL, Sales Volume, %, Russia, 2009–2010
Figure 24: Pricing and Reimbursement in Russia, Share of EDL in Total Russian Pharmaceutical Market, Sales Value, %, Russia, 2009–2010
Figure 25: Pricing and Reimbursement in Russia, Share of EDL in Total Russian Pharmaceutical Market, Sales Volume, %, Russia, 2009–2010
Figure 26: Pricing and Reimbursement in Russia, Number of DLO Beneficiaries, million, Russia, 2005–2010
Figure 27: Pricing and Reimbursement in Russia, Total Value of DLO Program, $bn, Russia, 2007–2010
Figure 28: Pricing and Reimbursement in Russia, Segmentation of DLO Sector Based on Sales Value of Domestic and Imported Drugs, 2009–2010
Figure 29: Pricing and Reimbursement in Russia, Segmentation of DLO Sector Based on Sales Volume of Domestic and Imported Drugs, 2008–2009
Figure 30: Pricing and Reimbursement in Russia, Top 10 Companies in DLO Sector, Sales Value, %, Russia, 2009–2010
Figure 31: Pricing and Reimbursement in Russia, Segmentation of Drugs in DLO Program by Price Range, Sales Value, %, 2009–2010
Figure 32: Pricing and Reimbursement in Russia, Segmentation of DLO Program, Sales Value. %, Russia, 2009–2010
Figure 33: Pricing and Reimbursement in Russia, Share of Nosologies in Seven Nosologies Program, Russia, 2008–2009
Figure 34: Pricing and Reimbursement in Russia, Share of Drugs in Seven Nosologies Program, %, 2009–2010
Figure 35: Pricing and Reimbursement in Russia, Share of Drugs in Seven Nosologies Program, Russia, 2008–2009
Figure 36: Pricing and Reimbursement in Russia, Price Segmentation of Drugs in VZN Program, Sales Value, %, 2009–2010
Figure 37: Pricing and Reimbursement in Russia, Segmentation of Drugs in ONLS Program by Price Range, Sales Value, %, Russia, 2009–2010
Figure 38: Pricing and Reimbursement in Russia, Private Insurance as a Percentage of Private Healthcare Expenditure, 2000–2009

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• Healthcare, Regulatory and Reimbursement Landscape Russia
• Russian Federation In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• Russian Federation Diagnostic Imaging Market Outlook to 2017 - Ultrasound Systems, MRI Systems, Computed Tomography Systems, Nuclear Imaging Equipment, X-Ray Systems, Mammography Equipment and Others
• Drug Delivery Devices Market Outlook in Russian Federation to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
• Russian Federation Ophthalmic Devices Market Outlook to 2017 - Vision Care, Ophthalmic Diagnostic Equipment, Cataract, Refractive, Vitreo Retinal and Glaucoma Surgery Devices
• Russian Federation In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• ENT Devices Market Outlook in Russian Federation to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices
• Nephrology and Urology Devices Market Outlook in Russian Federation to 2017 - Incontinence Devices, Renal Dialysis Equipment and Others
• Neurology Devices Market Outlook in Russian Federation to 2017 - Neurostimulation Devices, Interventional Neurology and Others
• Factors Influencing Morbidity Trends in BRIC Countries